Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database
Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting Sy...
Gespeichert in:
| Veröffentlicht in: | Scientific reports Jg. 14; H. 1; S. 16202 - 12 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
13.07.2024
Nature Publishing Group Nature Portfolio |
| Schlagworte: | |
| ISSN: | 2045-2322, 2045-2322 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide. |
|---|---|
| AbstractList | Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide. Abstract Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide. Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide.Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide. Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using the Food and Drug Administration Adverse Event Reporting System (FAERS). We performed disproportionality analysis computing reporting odds ratio (ROR) as a quantitative metric to assess the signal of lacosamide-related cardiac adverse events (AEs) from 2013 Q1 to 2022 Q4. The signal was considered significant when the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and ≥ 5 AEs were reported. Serious and nonserious cases were compared by statistical analysis, and signals were further prioritized using a rating scale. A total of 812 cardiac AEs associated with lacosamide were identified, and 92 signals were detected, of which 17 AEs were significantly associated signals. The median time-to-onset (TTO) for moderate priority signals was 10 days, whereas for weak priority signals, it was 54 days. Notably, all cardiac AEs exhibited an early failing pattern, indicating the risk gradually decreasing. Based on the comprehensive analysis of the FAERS database and prioritization of cardiac AE signals, our research enhances the awareness among healthcare professionals regarding cardiac AEs associated with lacosamide. |
| ArticleNumber | 16202 |
| Author | Chen, Huihui Yang, Chengcheng Zhao, Wanqi Yao, Yinhui Zhang, Jingmin |
| Author_xml | – sequence: 1 givenname: Chengcheng surname: Yang fullname: Yang, Chengcheng email: ycc424@163.com organization: Department of Pharmacy, The First People’s Hospital of Shangqiu – sequence: 2 givenname: Wanqi surname: Zhao fullname: Zhao, Wanqi organization: The University of Manchester – sequence: 3 givenname: Huihui surname: Chen fullname: Chen, Huihui organization: Department of Pharmacy, The First People’s Hospital of Shangqiu – sequence: 4 givenname: Yinhui surname: Yao fullname: Yao, Yinhui organization: Department of Pharmacy, Chengde Medical University Affiliated Hospital – sequence: 5 givenname: Jingmin surname: Zhang fullname: Zhang, Jingmin email: fcczhangjm@zzu.edu.cn organization: Department of Pharmacy, Henan Key Laboratory for Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39003359$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vEzEUXKEiWkL_AAdkiQuXBX_u2lxQFbVQqRIS9G699UfiaLMO9iZV_j1ON4W2h_ryLHtmNG_ee1udDHFwVfWe4M8EM_klcyKUrDHlddNSrGr8qjqjmIuaMkpPHt1Pq_OcV7gcQRUn6k11yhTGjAl1Vvk5JBvAILA7l7JDbueGMSPIOZoAo7PoLoxL1IOJGdbBuq8IkA15k-ImpjHEAfow7hGUus8ho-jRuHTo6uLy129kYYQOsntXvfbQZ3d-rLPq9urydv6jvvn5_Xp-cVMbwclYN0qWhlrZgTQKPGWM4dKll9LQpsPccCqYb9pWSGx9y4xwnndAiOLWGclm1fUkayOs9CaFNaS9jhD0_UNMCw3Fs-mdJrhrVOuZk9By3PmudR0GhpkXlrSuKVrfJq3Ntls7a0osCfonok9_hrDUi7jThFDecHFQ-HRUSPHP1uVRr0M2ru9hcHGbNcOtUqKhkhfox2fQVdymEukRhVtZsphVHx5b-uflYZwFICeASTHn5Lw2YYTDkIrD0Jem9WF59LQ8umSt75dH40Klz6gP6i-S2EQq6xCGhUv_bb_A-gsej9Ze |
| CitedBy_id | crossref_primary_10_1016_j_seizure_2024_10_011 crossref_primary_10_1007_s11096_025_01925_z crossref_primary_10_1080_02699052_2024_2424429 crossref_primary_10_3389_fneur_2025_1625612 crossref_primary_10_1016_j_seizure_2025_01_023 crossref_primary_10_1002_epi4_13098 crossref_primary_10_1097_MD_0000000000044365 crossref_primary_10_1097_MD_0000000000044497 crossref_primary_10_7759_cureus_88550 crossref_primary_10_3389_fphar_2025_1558128 |
| Cites_doi | 10.1007/s40263-018-0523-7 10.1016/j.eplepsyres.2021.106710 10.1111/ane.12416 10.4103/aian.AIAN_473_18 10.1111/j.1528-1167.2011.03212.x 10.2165/00023210-200923070-00002 10.3390/jcm10081660 10.1177/2047487320915663 10.1007/s11064-017-2234-8 10.1056/NEJM199212103272408 10.1007/s12012-018-9467-x 10.1111/jcpt.13024 10.1016/j.yebeh.2011.02.006 10.1146/annurev-pharmtox-010818-021757 10.1111/epi.13502 10.3389/fphar.2022.1075966 10.7759/cureus.20736 10.1016/S1474-4422(16)30292-7 10.1111/epi.13224 10.3109/15563650.2013.778993 10.1111/ane.12414 10.2147/CLEP.S365513 10.1080/14712598.2021.1948529 10.1080/14740338.2020.1713089 10.1080/17425255.2017.1360278 10.1111/apt.16601 10.1177/2168479013514236 10.3389/fneur.2022.891368 10.1111/j.1528-1167.2007.01188.x 10.1016/j.intimp.2021.107498 10.1111/epi.12108 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-024-67209-0 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_10b697f3e8a740bfb7eb0a303f5d17e6 PMC11246456 39003359 10_1038_s41598_024_67209_0 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Key Scientific and Technology Project of Henan Province grantid: 222102310358 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c541t-69802478ba8c9af23330598f88c26b04c4253f677580df73c5ef4ba1194dec83 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001272466300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Fri Oct 03 12:44:10 EDT 2025 Tue Nov 04 02:05:27 EST 2025 Thu Oct 02 06:23:47 EDT 2025 Tue Oct 07 09:06:10 EDT 2025 Thu Apr 03 07:08:15 EDT 2025 Sat Nov 29 02:13:35 EST 2025 Tue Nov 18 21:26:36 EST 2025 Fri Feb 21 02:37:52 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Disproportionality analyses Reporting odds ratio FAERS database Cardiac adverse events Lacosamide |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-69802478ba8c9af23330598f88c26b04c4253f677580df73c5ef4ba1194dec83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3079907833?pq-origsite=%requestingapplication% |
| PMID | 39003359 |
| PQID | 3079907833 |
| PQPubID | 2041939 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_10b697f3e8a740bfb7eb0a303f5d17e6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11246456 proquest_miscellaneous_3079956284 proquest_journals_3079907833 pubmed_primary_39003359 crossref_citationtrail_10_1038_s41598_024_67209_0 crossref_primary_10_1038_s41598_024_67209_0 springer_journals_10_1038_s41598_024_67209_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-13 |
| PublicationDateYYYYMMDD | 2024-07-13 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Gatti, Antonazzo, Diemberger, De Ponti, Raschi (CR31) 2021; 28 Yadav, Schrem, Yadav (CR12) 2021; 13 Kinoshita, Hosomi, Yokoyama, Takada (CR35) 2020; 45 Malissin, Baud, Deveaux (CR25) 2013; 51 CR16 CR15 Vestergaard Kvist, Faruque, Vallejo-Yague (CR29) 2021; 10 CR33 Bhana, Chourasiya, Desai (CR24) 2019; 22 Shu, He, Liu, Wu, Zhang (CR27) 2022; 14 Guo, Wang, Yuan (CR32) 2022; 13 Baulac, Rosenow, Toledo (CR3) 2017; 16 Catterall, Lenaeus, Gamal El-Din (CR4) 2020; 60 Rudd, Haverkamp, Mason (CR22) 2015; 132 Nizam, Mylavarapu, Thomas (CR14) 2011; 52 de Biase, Valente, Gigli, Merlino (CR2) 2017; 13 Lu, Lin, Ho, Hsu, Tsai (CR8) 2022; 13 Curia, Biagini, Perucca, Avoli (CR5) 2009; 23 Krause, Brodowski, Kellinghaus (CR13) 2011; 20 Chinnasami, Rathore, Duncan (CR18) 2013; 54 Kropeit, Johnson, Cawello, Rudd, Horstmann (CR19) 2015; 132 Wichelmann, Abdulmujeeb, Ehrenpreis (CR30) 2021; 54 Li, Sun, Wang (CR7) 2020; 19 CR28 Mazhar, Battini, Gringeri (CR26) 2021; 21 Kim, Lee, Bae, Kim (CR11) 2021; 176 Chen, Wu, Zhang, Xu (CR34) 2021; 95 Svendsen, Brodtkorb, Baftiu (CR6) 2017; 42 Huang, Guo, Zalkikar, Tiwari (CR17) 2014; 48 Runge, Arnold, Brandt (CR20) 2015; 56 Wei (CR21) 1992; 327 Hoy (CR1) 2018; 32 Lachuer, Corny, Bezie, Ferchichi, Durand-Gasselin (CR23) 2018; 18 Ben-Menachem, Biton, Jatuzis (CR9) 2007; 48 Vossler, Wechsler, Williams (CR10) 2016; 57 YT Lu (67209_CR8) 2022; 13 H Guo (67209_CR32) 2022; 13 E Ben-Menachem (67209_CR9) 2007; 48 F Mazhar (67209_CR26) 2021; 21 R Yadav (67209_CR12) 2021; 13 S Chinnasami (67209_CR18) 2013; 54 C Lachuer (67209_CR23) 2018; 18 67209_CR28 M Baulac (67209_CR3) 2017; 16 TA Wichelmann (67209_CR30) 2021; 54 JY Wei (67209_CR21) 1992; 327 G Curia (67209_CR5) 2009; 23 A Vestergaard Kvist (67209_CR29) 2021; 10 S de Biase (67209_CR2) 2017; 13 D Kropeit (67209_CR19) 2015; 132 SM Hoy (67209_CR1) 2018; 32 WA Catterall (67209_CR4) 2020; 60 LU Krause (67209_CR13) 2011; 20 M Gatti (67209_CR31) 2021; 28 J Li (67209_CR7) 2020; 19 67209_CR33 U Runge (67209_CR20) 2015; 56 DG Vossler (67209_CR10) 2016; 57 I Malissin (67209_CR25) 2013; 51 C Chen (67209_CR34) 2021; 95 A Nizam (67209_CR14) 2011; 52 HK Kim (67209_CR11) 2021; 176 67209_CR15 67209_CR16 L Huang (67209_CR17) 2014; 48 Y Shu (67209_CR27) 2022; 14 S Kinoshita (67209_CR35) 2020; 45 T Svendsen (67209_CR6) 2017; 42 IG Bhana (67209_CR24) 2019; 22 GD Rudd (67209_CR22) 2015; 132 |
| References_xml | – volume: 32 start-page: 473 year: 2018 end-page: 484 ident: CR1 article-title: Lacosamide: A review in focal-onset seizures in patients with epilepsy publication-title: CNS Drugs doi: 10.1007/s40263-018-0523-7 – volume: 176 year: 2021 ident: CR11 article-title: Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy publication-title: Epilepsy Res. doi: 10.1016/j.eplepsyres.2021.106710 – volume: 132 start-page: 346 year: 2015 end-page: 354 ident: CR19 article-title: Lacosamide cardiac safety: A thorough QT/QTc trial in healthy volunteers publication-title: Acta Neurol. Scand. doi: 10.1111/ane.12416 – volume: 22 start-page: 529 year: 2019 end-page: 530 ident: CR24 article-title: Lacosamide associated complete heart block in elderly publication-title: Ann. Indian Acad. Neurol. doi: 10.4103/aian.AIAN_473_18 – volume: 52 start-page: e153 year: 2011 end-page: 155 ident: CR14 article-title: Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy publication-title: Epilepsia doi: 10.1111/j.1528-1167.2011.03212.x – volume: 23 start-page: 555 year: 2009 end-page: 568 ident: CR5 article-title: Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders publication-title: CNS Drugs doi: 10.2165/00023210-200923070-00002 – ident: CR16 – volume: 10 start-page: 1660 year: 2021 ident: CR29 article-title: Cardiovascular safety profile of romosozumab: A pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS) publication-title: J. Clin. Med. doi: 10.3390/jcm10081660 – volume: 28 start-page: 983 year: 2021 end-page: 989 ident: CR31 article-title: Adverse events with sacubitril/valsartan in the real world: Emerging signals to target preventive strategies from the FDA adverse event reporting system publication-title: Eur. J. Prev. Cardiol. doi: 10.1177/2047487320915663 – volume: 42 start-page: 2077 year: 2017 end-page: 2083 ident: CR6 article-title: Therapeutic Drug monitoring of lacosamide in Norway: Focus on pharmacokinetic variability, efficacy and tolerability publication-title: Neurochem. Res. doi: 10.1007/s11064-017-2234-8 – volume: 327 start-page: 1735 year: 1992 end-page: 1739 ident: CR21 article-title: Age and the cardiovascular system publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199212103272408 – ident: CR33 – volume: 18 start-page: 579 year: 2018 end-page: 582 ident: CR23 article-title: Complete atrioventricular block in an elderly patient treated with low-dose lacosamide publication-title: Cardiovasc. Toxicol. doi: 10.1007/s12012-018-9467-x – volume: 45 start-page: 65 year: 2020 end-page: 71 ident: CR35 article-title: Time-to-onset analysis of amiodarone-associated thyroid dysfunction publication-title: J. Clin. Pharm. Ther. doi: 10.1111/jcpt.13024 – volume: 20 start-page: 725 year: 2011 end-page: 727 ident: CR13 article-title: Atrioventricular block following lacosamide intoxication publication-title: Epilepsy Behav. doi: 10.1016/j.yebeh.2011.02.006 – volume: 60 start-page: 133 year: 2020 end-page: 154 ident: CR4 article-title: Structure and pharmacology of voltage-gated sodium and calcium channels publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev-pharmtox-010818-021757 – volume: 57 start-page: 1625 year: 2016 end-page: 1633 ident: CR10 article-title: Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial publication-title: Epilepsia doi: 10.1111/epi.13502 – volume: 13 start-page: 1075966 year: 2022 ident: CR32 article-title: Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.1075966 – volume: 13 year: 2021 ident: CR12 article-title: Lacosamide-related arrhythmias: A systematic analysis and review of the literature publication-title: Cureus doi: 10.7759/cureus.20736 – volume: 16 start-page: 43 year: 2017 end-page: 54 ident: CR3 article-title: Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: A phase 3, randomised, double-blind, non-inferiority trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)30292-7 – ident: CR15 – volume: 56 start-page: 1921 year: 2015 end-page: 1930 ident: CR20 article-title: A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study publication-title: Epilepsia doi: 10.1111/epi.13224 – volume: 51 start-page: 381 year: 2013 end-page: 382 ident: CR25 article-title: Fatal lacosamide poisoning in relation to cardiac conduction impairment and cardiovascular failure publication-title: Clin. Toxicol. (Phila) doi: 10.3109/15563650.2013.778993 – volume: 132 start-page: 355 year: 2015 end-page: 363 ident: CR22 article-title: Lacosamide cardiac safety: Clinical trials in patients with partial-onset seizures publication-title: Acta Neurol. Scand. doi: 10.1111/ane.12414 – volume: 14 start-page: 789 year: 2022 end-page: 802 ident: CR27 article-title: A Real-world disproportionality analysis of olaparib: Data mining of the public version of FDA adverse event reporting system publication-title: Clin. Epidemiol. doi: 10.2147/CLEP.S365513 – volume: 21 start-page: 1281 year: 2021 end-page: 1290 ident: CR26 article-title: The impact of anti-TNFalpha agents on weight-related changes: New insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database publication-title: Expert Opin. Biol. Ther. doi: 10.1080/14712598.2021.1948529 – volume: 19 start-page: 131 year: 2020 end-page: 138 ident: CR7 article-title: The adverse-effect profile of lacosamide publication-title: Expert Opin. Drug Saf. doi: 10.1080/14740338.2020.1713089 – volume: 13 start-page: 997 year: 2017 end-page: 1005 ident: CR2 article-title: Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures publication-title: Expert Opin. Drug. Metab Toxicol. doi: 10.1080/17425255.2017.1360278 – volume: 54 start-page: 1290 year: 2021 end-page: 1297 ident: CR30 article-title: Bevacizumab and gastrointestinal perforations: A review from the FDA Adverse Event Reporting System (FAERS) database publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/apt.16601 – volume: 48 start-page: 98 year: 2014 end-page: 108 ident: CR17 article-title: A review of statistical methods for safety surveillance publication-title: Ther. Innov. Regul. Sci. doi: 10.1177/2168479013514236 – ident: CR28 – volume: 13 year: 2022 ident: CR8 article-title: Evaluation of cardiovascular concerns of intravenous lacosamide therapy in epilepsy patients publication-title: Front. Neurol. doi: 10.3389/fneur.2022.891368 – volume: 48 start-page: 1308 year: 2007 end-page: 1317 ident: CR9 article-title: Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures publication-title: Epilepsia doi: 10.1111/j.1528-1167.2007.01188.x – volume: 95 year: 2021 ident: CR34 article-title: Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2021.107498 – volume: 54 start-page: e90 year: 2013 end-page: 93 ident: CR18 article-title: Sinus node dysfunction: An adverse effect of lacosamide publication-title: Epilepsia doi: 10.1111/epi.12108 – ident: 67209_CR28 – volume: 13 start-page: 1075966 year: 2022 ident: 67209_CR32 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.1075966 – volume: 28 start-page: 983 year: 2021 ident: 67209_CR31 publication-title: Eur. J. Prev. Cardiol. doi: 10.1177/2047487320915663 – ident: 67209_CR16 – volume: 51 start-page: 381 year: 2013 ident: 67209_CR25 publication-title: Clin. Toxicol. (Phila) doi: 10.3109/15563650.2013.778993 – volume: 56 start-page: 1921 year: 2015 ident: 67209_CR20 publication-title: Epilepsia doi: 10.1111/epi.13224 – volume: 60 start-page: 133 year: 2020 ident: 67209_CR4 publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev-pharmtox-010818-021757 – volume: 48 start-page: 98 year: 2014 ident: 67209_CR17 publication-title: Ther. Innov. Regul. Sci. doi: 10.1177/2168479013514236 – volume: 176 year: 2021 ident: 67209_CR11 publication-title: Epilepsy Res. doi: 10.1016/j.eplepsyres.2021.106710 – volume: 48 start-page: 1308 year: 2007 ident: 67209_CR9 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2007.01188.x – volume: 132 start-page: 346 year: 2015 ident: 67209_CR19 publication-title: Acta Neurol. Scand. doi: 10.1111/ane.12416 – volume: 32 start-page: 473 year: 2018 ident: 67209_CR1 publication-title: CNS Drugs doi: 10.1007/s40263-018-0523-7 – volume: 16 start-page: 43 year: 2017 ident: 67209_CR3 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(16)30292-7 – volume: 132 start-page: 355 year: 2015 ident: 67209_CR22 publication-title: Acta Neurol. Scand. doi: 10.1111/ane.12414 – volume: 22 start-page: 529 year: 2019 ident: 67209_CR24 publication-title: Ann. Indian Acad. Neurol. doi: 10.4103/aian.AIAN_473_18 – ident: 67209_CR33 – volume: 327 start-page: 1735 year: 1992 ident: 67209_CR21 publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199212103272408 – volume: 54 start-page: 1290 year: 2021 ident: 67209_CR30 publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/apt.16601 – volume: 13 start-page: 997 year: 2017 ident: 67209_CR2 publication-title: Expert Opin. Drug. Metab Toxicol. doi: 10.1080/17425255.2017.1360278 – volume: 10 start-page: 1660 year: 2021 ident: 67209_CR29 publication-title: J. Clin. Med. doi: 10.3390/jcm10081660 – volume: 52 start-page: e153 year: 2011 ident: 67209_CR14 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2011.03212.x – volume: 54 start-page: e90 year: 2013 ident: 67209_CR18 publication-title: Epilepsia doi: 10.1111/epi.12108 – volume: 13 year: 2021 ident: 67209_CR12 publication-title: Cureus doi: 10.7759/cureus.20736 – volume: 20 start-page: 725 year: 2011 ident: 67209_CR13 publication-title: Epilepsy Behav. doi: 10.1016/j.yebeh.2011.02.006 – volume: 19 start-page: 131 year: 2020 ident: 67209_CR7 publication-title: Expert Opin. Drug Saf. doi: 10.1080/14740338.2020.1713089 – volume: 23 start-page: 555 year: 2009 ident: 67209_CR5 publication-title: CNS Drugs doi: 10.2165/00023210-200923070-00002 – volume: 57 start-page: 1625 year: 2016 ident: 67209_CR10 publication-title: Epilepsia doi: 10.1111/epi.13502 – volume: 95 year: 2021 ident: 67209_CR34 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2021.107498 – volume: 13 year: 2022 ident: 67209_CR8 publication-title: Front. Neurol. doi: 10.3389/fneur.2022.891368 – volume: 21 start-page: 1281 year: 2021 ident: 67209_CR26 publication-title: Expert Opin. Biol. Ther. doi: 10.1080/14712598.2021.1948529 – ident: 67209_CR15 – volume: 42 start-page: 2077 year: 2017 ident: 67209_CR6 publication-title: Neurochem. Res. doi: 10.1007/s11064-017-2234-8 – volume: 18 start-page: 579 year: 2018 ident: 67209_CR23 publication-title: Cardiovasc. Toxicol. doi: 10.1007/s12012-018-9467-x – volume: 14 start-page: 789 year: 2022 ident: 67209_CR27 publication-title: Clin. Epidemiol. doi: 10.2147/CLEP.S365513 – volume: 45 start-page: 65 year: 2020 ident: 67209_CR35 publication-title: J. Clin. Pharm. Ther. doi: 10.1111/jcpt.13024 |
| SSID | ssj0000529419 |
| Score | 2.481917 |
| Snippet | Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still... Abstract Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 16202 |
| SubjectTerms | 631/154/1438 631/154/570 Adolescent Adult Adverse Drug Reaction Reporting Systems - statistics & numerical data Adverse events Aged Anticonvulsants - adverse effects Antiepileptic agents Cardiac adverse events Cardiac arrest Cardiac arrhythmia Cardiotoxicity - epidemiology Cardiotoxicity - etiology Clinical trials Databases, Factual Diabetic neuropathy Disproportionality analyses Drugs Epilepsy FAERS database FDA approval Female Heart Hospitals Humanities and Social Sciences Humans Lacosamide Lacosamide - adverse effects Male Middle Aged multidisciplinary Pharmacy Reporting odds ratio Science Science (multidisciplinary) Statistical analysis United States - epidemiology United States Food and Drug Administration Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQVSQuqOWZUpCRuEFEEjt-cCtVV5wqBD30ZvkpIpUsarZI_fedcbxLl-eFazJJJvPwjD32N4S86qXvhUuhblxyNU9C1KqLvGYsuiA6bn1KudmEPD1V5-f6461WX7gnbIYHngUHXu2ElolFZSXHF8roGgsDb-pDK2MG226kvjWZmlG9O81bXU7JNEy9nSBS4WmyjtdCdlgR2IpEGbD_d1nmr5slf6qY5kC02CP3SwZJj2bO98mdOD4gd-eektcPSTrOOvfUYqvlKdIM0TRRW_QQA8W1V3oBQ-Fkvw4hvqOWhgE-t8RcfCipObUFroQuE4UskS6OTj59prijFCPfI3K2ODk7_lCXZgq173m7qoVW8O9SOau8tqljDDxdq6SU74RruAfnZUlImD80IUnm-5i4s22reYhescdkZ1yO8SmhQOKx63r0GZunVVF4rxEYDOZqPIWKtGu5Gl-AxrHfxYXJBW-mzKwLA_yYrAvTVOT15plvM8zGX6nfo7o2lAiRnS-A4ZhiOOZfhlORw7WyTfHbycCIB-FZKsYq8nJzGzwOyyh2jMurQgNpo-IVeTLbxoYThgvDrNcVUVtWs8Xq9p1x-JJRvSHxxSoz8PVmbWA_-PqzLA7-hyyekXsdegYChrJDsrO6vIrPya7_vhqmyxfZtW4ANSsmDg priority: 102 providerName: Directory of Open Access Journals |
| Title | Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database |
| URI | https://link.springer.com/article/10.1038/s41598-024-67209-0 https://www.ncbi.nlm.nih.gov/pubmed/39003359 https://www.proquest.com/docview/3079907833 https://www.proquest.com/docview/3079956284 https://pubmed.ncbi.nlm.nih.gov/PMC11246456 https://doaj.org/article/10b697f3e8a740bfb7eb0a303f5d17e6 |
| Volume | 14 |
| WOSCitedRecordID | wos001272466300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCxIX3o9AWRmJG0RNYsd2uKC22hUculqVHpZT5Dg2RCpJ2WyR-PfMON5Uy6MXLj4kjjT2PD3jfEPI61yaXFSujpPKVTF3QsQqszxmzFa1yLg2zvlmE3KxUKtVsQwJtz5cq9zaRG-o685gjvwAZBEMp1SMvb_4HmPXKKyuhhYaN8kE22ajnMuVHHMsWMXiaRH-lUmYOujBX-E_ZRmPhcywLrDjjzxs_99izT-vTP5WN_XuaH7vfxdyn9wNgSg9HCTnAblh24fk9tCa8ucj4o696BiqsWNzb6lHeuqpDuy0NcUULj0Hi9rrb01t31FN6wbo7TCkb0KET3VAPaGdoxBs0vnh7PQTxYup6EAfk7P57Oz4Qxx6MsQm5-kmFoWCzZOq0soU2mWMgcEolFPKZKJKuAEbwJyQcAxJaieZya3jlU7TgtfWKPaE7LVda58RClMMNm-3xkP8pMoKYwrEF4MjH3d1RNItY0oT8MqxbcZ56evmTJUDM0ugp_TMLJOIvBm_uRjQOq6dfYT8Hmci0rZ_0K2_lEFx4dtKFNIxqzQQBgItbZVocPwur1NpRUT2t2wug_r35RWPI_JqfA2Ki9UY3druMsyB6FPxiDwdhGukhGF-meVFRNSO2O2Quvumbb56cHCIn7FYDXS93UroFV3_3ovn1y_jBbmTodIgoijbJ3ub9aV9SW6ZH5umX0-91vlRTcnkaLZYnk59cgPGk2yJo4Rxsvx4svz8C_fTOsI |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLQguvB-BAkaCE0RNYsdxkBAqpauu2q5WsIdyshzHhkhlUzZbUH8U_5Gxk2y1PHrrgWs8jibONy-PPQPwPM10ygtbhlFhi5BZzkORGBZSaoqSJ0xpa32ziWw8FoeH-WQNfvZ3Ydyxyl4nekVd1trtkW8iFlFxZoLSt8ffQtc1ymVX-xYaLSz2zOkPDNmaN6P3-H9fJMlwZ7q9G3ZdBUKdsngR8lygXcpEoYTOlU0oRvRpLqwQOuFFxDSimFqeoSMdlTajOjWWFSrGaL80WlB87SVYZ0gVDWB9MjqYfFpu6ri0GYvz7nJORMVmgwbSXWJLWMizxCUiVgyg7xPwN-f2zzOavyVqvf0b3vjPVu4mXO8cbbLVSsYtWDOz23Clbb15egfsthcNTZTrSN0Y4itZNUR1cDUlcVvU5AgtRqO-VqV5TRQpK1ye2oUsVRfBENVVdSG1JehMk-HWzoePxB28dQ7CXZhexDfeg8GsnpkHQJBEu-b0RvsSRrEwXOvc1U_DkJbZMoC4x4HUXT121xbkSPpzAVTIFjsS-ZEeOzIK4OVyznFbjeRc6ncOXktKV0ncP6jnn2WnmHBuwfPMUiMUMoYCm5kiUujY2LSMM8MD2OhRJTv11sgzSAXwbDmMisllm9TM1CcdDXrXggVwv8XykhPq9s9pmgcgVlC-wurqyKz64oufY3zgkvHI16teIM74-vdaPDz_M57C1d3pwb7cH433HsG1xMmrq55KN2CwmJ-Yx3BZf19UzfxJJ_IE5AWLyi8sTo9H |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLSAuvB-BAkaCE0SbxIntICHU14qqaLUqPfRmOY4NK5VN2WxB_Wn8O8aOs9Xy6K0HrrEdTZxvXp7xDMDLguuCVbaOk8pWcW4Zi0Vm8phSU9Usy5W21jeb4OOxODoqJ2vws78L49Iqe5noBXXdaHdGPkQsouDkgtKhDWkRk53R-5Nvsesg5SKtfTuNDiL75uwHum_tu70d_Nevsmy0e7j9IQ4dBmJd5OkiZqVAHcVFpYQulc0oevdFKawQOmNVkmtENLWMo1Gd1JZTXRibVypFz782WlB87RVY5xR9ngGsb-2OJwfLAx4XQsvTMlzUSagYtqgs3YW2LI8Zz1xQYkUZ-p4BfzN0_8zX_C1o63Xh6NZ_vIu34WYwwMlmxzF3YM3M7sK1riXn2T2w255lNFGuU3VriK9w1RIVYGxq4o6uyTFqklZ9ndbmLVGknuJWNc6VmQbPhqhQ7YU0lqCRTUabuwefiEvIdYbDfTi8jG98AINZMzOPgOAU7ZrWG-1LG6XCMK1LV1cNXd3c1hGkPSakDnXaXbuQY-nzBaiQHY4k0iM9jmQSwevlmpOuSsmFs7cc1JYzXYVx_6CZf5ZBYOHaipXcUiMUEoaMzE2VKDR4bFGn3LAINnqEySD2WnkOrwheLIdRYLkolJqZ5jTMQatb5BE87HC9pIS6c3ValBGIFcSvkLo6Mpt-8UXR0W9wQXqk603PHOd0_XsvHl_8Gc_hOvKH_Lg33n8CNzLHuq6oKt2AwWJ-ap7CVf19MW3nzwL3E5CXzCm_AITFl-E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiac+adverse+events+associated+with+lacosamide%3A+a+disproportionality+analysis+of+the+FAERS+database&rft.jtitle=Scientific+reports&rft.au=Yang%2C+Chengcheng&rft.au=Zhao%2C+Wanqi&rft.au=Chen%2C+Huihui&rft.au=Yao%2C+Yinhui&rft.date=2024-07-13&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft.spage=16202&rft_id=info:doi/10.1038%2Fs41598-024-67209-0&rft_id=info%3Apmid%2F39003359&rft.externalDocID=39003359 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |